Phase 3 SOPHIA study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in patients (pts) with HER2+metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysisHope Rugo,Seock-Ah Im,Fatima Cardoso,Javier Cortes,Giuseppe Curigliano,Antonino Musolino,Mark D. Pegram,Thomas Bachelot,Gail S. Wright,Cristina Saura,Santiago Escriva-de-Romani,Michelino De laurentiis, Gary N. Schwartz,Timothy Pluard,Francesco Ricci, William Gwin,Christelle Levy,Ursa Brown-Glaberman,Jean-Marc Ferrero,Maaike de Boer,Sung-Bae Kim,Katarina Petrakova,Denise A. Yardley,Orit Freedman,Erik H. Jakobsen,Einav Nili Gal-Yam,Rinat Yerushalmi,Peter A. Fasching, Emily Ashley,Shengyan Hong,Minori Rosales,William J. GradisharCANCER RESEARCH（2022）引用 3|浏览29暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
